There are several potential challengers to Novo Nordisk and Eli Lilly’s obesity drugs, and Jefferies analysts see one as ...

Hims & Hers’ decision to advertise at the Super Bowl represents an ambitious play for the brand as it positions itself in the ...

Telehealth provider will make its big game debut as the semaglutide shortage continues to sustain the firm’s lower-priced ...

BioSpace recaps 2024’s top venture capital rounds in biopharma, from Xaira Therapeutics’ blockbuster $1B raise to ...

This is an audio transcript of the FT News Briefing podcast episode: ‘Trump steers the world towards a tax war’ Sonja Hutson Good morning from the Financial Times. Today is Friday, January 24th. And ...

Just as Gore’s song resonated with audiences 60 years ago thanks to its ... Still, he stresses that Currax isn’t competing directly with GLP-1 manufacturing giants Novo Nordisk and Eli Lilly, nor does ...

LOW: Not actually getting to see Nikki Glaser’s “Pope-ular” song in full ... brought to you by their sponsor, Eli Lilly and Company. The joys of watching live CBS. HIGH: Sexy tennis music ...

China has become a key piece of Foresite Capital’s investment and company formation strategy. During the J.P. Morgan Healthcare Conference, Managing Director Michael Rome shared his thoughts on why ...

Coming four years after her last record, Forever is Lilly Hiatt’s strongest blend yet of alt-rock guitars with Americana ...

Eli Lilly's Ozempic-rivaling weight-loss pill orforglipron could be available in early 2026. Its retatrutide may be as ...

Weight loss treatments Mounjaro and Zepbound are the primary growth engines for Eli Lilly right now, but the company has another enormous opportunity that's getting very little attention.